Yesterday was painful. It will take time to recover. It hurts. Despite many months of clinical and preclinical execution along with successful financings, we had to abruptly reduce our operations and let go of colleagues. 18 great team members. 18 good people. It cut across the entire organization – clinical, translational, preclinical, CMC, microbiology, finance, legal and administrative. Life disrupted. Lives disrupted. Please comment to this post if you believe you have an opportunity for any of our people. They can then connect and hopefully good things may come from this unfortunate event.
ContraFect Corp
Biotechnology Research
Yonkers, NY 3,431 followers
...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections
About us
We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.
- Website
-
http://www.contrafect.com
External link for ContraFect Corp
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Yonkers, NY
- Type
- Public Company
- Founded
- 2008
Locations
-
Primary
Get directions
28 Wells Avenue
Yonkers, NY, US
Employees at ContraFect Corp
-
Brittany La
Assistant General Counsel, Intellectual Property at ContraFect Corp
-
Keren Marshal
Sr. Executive Assistant to Chairman & CEO and General Counsel at PAVM | LUCD
-
Jerry Kiciuk, CMRP
Facility Manager at ContraFect Corp
-
Amit Gangar
Director, Formulation & Drug Product Development
Updates
-
On Friday, we submitted the IND application to the FDA for CF-370! We are doing what few others are...developing NEW mechanisms to treat severe, life-threatening infections. The lytic action is unprecedented in the fight against Gram-negative pathogens. Thank you to all the players (too many to name) at ContraFect who made this happen. We can make the difference for patients infected by the most dangerous bacterial pathogens in the world.
-